KR20020052072A - 초음파 조영제 및 그의 제조방법 - Google Patents
초음파 조영제 및 그의 제조방법 Download PDFInfo
- Publication number
- KR20020052072A KR20020052072A KR1020000081255A KR20000081255A KR20020052072A KR 20020052072 A KR20020052072 A KR 20020052072A KR 1020000081255 A KR1020000081255 A KR 1020000081255A KR 20000081255 A KR20000081255 A KR 20000081255A KR 20020052072 A KR20020052072 A KR 20020052072A
- Authority
- KR
- South Korea
- Prior art keywords
- contrast agent
- contrast
- pbs
- microbubbles
- inert gas
- Prior art date
Links
- 239000002872 contrast media Substances 0.000 title claims abstract description 59
- 238000004519 manufacturing process Methods 0.000 title description 6
- 239000011261 inert gas Substances 0.000 claims abstract description 17
- 238000000034 method Methods 0.000 claims abstract description 6
- 238000000227 grinding Methods 0.000 claims abstract description 3
- 229920000136 polysorbate Polymers 0.000 claims description 12
- 239000007789 gas Substances 0.000 claims description 9
- IYFATESGLOUGBX-YVNJGZBMSA-N Sorbitan monopalmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O IYFATESGLOUGBX-YVNJGZBMSA-N 0.000 claims description 5
- 238000002156 mixing Methods 0.000 claims description 5
- 238000011049 filling Methods 0.000 claims description 4
- 238000003756 stirring Methods 0.000 claims description 4
- QYSGYZVSCZSLHT-UHFFFAOYSA-N octafluoropropane Chemical compound FC(F)(F)C(F)(F)C(F)(F)F QYSGYZVSCZSLHT-UHFFFAOYSA-N 0.000 claims description 3
- KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 claims description 2
- YCKRFDGAMUMZLT-UHFFFAOYSA-N Fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 claims description 2
- 229910018503 SF6 Inorganic materials 0.000 claims description 2
- 229910052731 fluorine Inorganic materials 0.000 claims description 2
- 239000011737 fluorine Substances 0.000 claims description 2
- 229960004692 perflenapent Drugs 0.000 claims description 2
- 229960004624 perflexane Drugs 0.000 claims description 2
- KAVGMUDTWQVPDF-UHFFFAOYSA-N perflubutane Chemical compound FC(F)(F)C(F)(F)C(F)(F)C(F)(F)F KAVGMUDTWQVPDF-UHFFFAOYSA-N 0.000 claims description 2
- 229950003332 perflubutane Drugs 0.000 claims description 2
- ZJIJAJXFLBMLCK-UHFFFAOYSA-N perfluorohexane Chemical compound FC(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)F ZJIJAJXFLBMLCK-UHFFFAOYSA-N 0.000 claims description 2
- NJCBUSHGCBERSK-UHFFFAOYSA-N perfluoropentane Chemical compound FC(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)F NJCBUSHGCBERSK-UHFFFAOYSA-N 0.000 claims description 2
- 238000002360 preparation method Methods 0.000 claims description 2
- SFZCNBIFKDRMGX-UHFFFAOYSA-N sulfur hexafluoride Chemical compound FS(F)(F)(F)(F)F SFZCNBIFKDRMGX-UHFFFAOYSA-N 0.000 claims description 2
- 229960000909 sulfur hexafluoride Drugs 0.000 claims description 2
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 claims 3
- -1 perfluoro Chemical group 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 12
- 230000002685 pulmonary effect Effects 0.000 abstract description 5
- 239000002961 echo contrast media Substances 0.000 abstract description 3
- 239000000203 mixture Substances 0.000 abstract description 3
- 230000002861 ventricular Effects 0.000 abstract 3
- 238000013019 agitation Methods 0.000 abstract 1
- 230000003014 reinforcing effect Effects 0.000 abstract 1
- 238000002592 echocardiography Methods 0.000 description 12
- 239000002953 phosphate buffered saline Substances 0.000 description 12
- 210000005240 left ventricle Anatomy 0.000 description 10
- 210000005241 right ventricle Anatomy 0.000 description 10
- 239000000243 solution Substances 0.000 description 10
- 210000004369 blood Anatomy 0.000 description 8
- 239000008280 blood Substances 0.000 description 8
- 238000002604 ultrasonography Methods 0.000 description 6
- 210000004072 lung Anatomy 0.000 description 4
- 210000004165 myocardium Anatomy 0.000 description 4
- 239000004094 surface-active agent Substances 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 3
- 238000000527 sonication Methods 0.000 description 3
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- 108010056388 Albunex Proteins 0.000 description 1
- 208000005189 Embolism Diseases 0.000 description 1
- 108010008908 FS 069 Proteins 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 241000276498 Pollachius virens Species 0.000 description 1
- 229920001219 Polysorbate 40 Polymers 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 230000003190 augmentative effect Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 239000010419 fine particle Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 230000000004 hemodynamic effect Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 229960004065 perflutren Drugs 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 238000002310 reflectometry Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 235000011071 sorbitan monopalmitate Nutrition 0.000 description 1
- 229940031953 sorbitan monopalmitate Drugs 0.000 description 1
- 239000001570 sorbitan monopalmitate Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/22—Echographic preparations; Ultrasound imaging preparations ; Optoacoustic imaging preparations
- A61K49/222—Echographic preparations; Ultrasound imaging preparations ; Optoacoustic imaging preparations characterised by a special physical form, e.g. emulsions, liposomes
- A61K49/223—Microbubbles, hollow microspheres, free gas bubbles, gas microspheres
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Acoustics & Sound (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Physics & Mathematics (AREA)
- Radiology & Medical Imaging (AREA)
- Inorganic Chemistry (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Description
Claims (8)
- (a) PBS 1 mL 당 0.005 내지 1 mL의 트윈(tween);(b) PBS 1 mL 당 0.005 g 내지 1 g의 스팬(span); 및(c) 불활성 가스를 포함하는 것을 특징으로 하는 조영제.
- 제 1항에 있어서, 조영제의 미세기포 95 %이상이 직경 10 um 이하인 미세기포를 포함하는 것을 특징으로 하는 조영제.
- 제 1항에 있어서, 조영제는 mL 당 1.0 x 107내지 1.0 x 109개의 미세기포를 포함하는 것을 특징으로 하는 조영제.
- 제 1항에 있어서, 상기 트윈은 트윈 40인 것을 특징으로 하는 조영제.
- 제 1항에 있어서, 상기 스팬은 스팬 40인 것을 특징으로 하는 조영제.
- 제 1항에 있어서, 상기 불활성 가스는 불소가스가 포함된 불화물인 것을 특징으로 하는 조영제.
- 제 1항 또는 제 6항에 있어서, 상기 불활성 가스는 퍼플루오로프로 perfluoropropan), 설퍼 헥사플루오라이드(sulfur hexafluoride), 퍼플루오로펜탄 (perfluoropentane), 데카플루오로부탄(decafluorobutane), 및 퍼플루오로헥산 (perfluorohexane)으로 이루어진 군으로부터 선택되어지는 것을 특징으로 하는 조영제.
- (a) 트윈과 PBS를 교반하는 단계;(b) 스팬과 PBS를 교반하는 단계;(c) 상기 a)단계의 용액과 b)단계의 용액을 혼합한 다음 불활성 가스를 충진하는 단계; 및(d) 상기 (c)단계의 불활성 가스가 충진된 용액을 초음파 분쇄하는 단계를 포함하는 것을 특징으로 하는 조영제 제조방법.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2000-0081255A KR100373712B1 (ko) | 2000-12-23 | 2000-12-23 | 초음파 조영제 및 그의 제조방법 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2000-0081255A KR100373712B1 (ko) | 2000-12-23 | 2000-12-23 | 초음파 조영제 및 그의 제조방법 |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20020052072A true KR20020052072A (ko) | 2002-07-02 |
KR100373712B1 KR100373712B1 (ko) | 2003-02-25 |
Family
ID=27685380
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR10-2000-0081255A KR100373712B1 (ko) | 2000-12-23 | 2000-12-23 | 초음파 조영제 및 그의 제조방법 |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR100373712B1 (ko) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2015133828A1 (ko) * | 2014-03-07 | 2015-09-11 | 주식회사 퍼시픽시스템 | 약물 전달을 위해 기포를 포함하는 미셀 및 이를 제작하는 방법 |
KR20150105228A (ko) * | 2014-03-07 | 2015-09-16 | 주식회사 퍼시픽시스템 | 약물 전달을 위해 기포를 포함하는 미셀 및 이를 제작하는 방법 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5798091A (en) * | 1993-07-30 | 1998-08-25 | Alliance Pharmaceutical Corp. | Stabilized gas emulsion containing phospholipid for ultrasound contrast enhancement |
EP0699445A3 (en) * | 1994-08-04 | 1996-04-17 | Gakko Houjin Toin Gakuen | Process for the preparation of an ultrasonic microbubble contrast agent with a surfactant |
FR2735482B1 (fr) * | 1995-06-14 | 1997-08-29 | Rhone Poulenc Chimie | Composition pour polymere chlore a base de beta-dicetone et d'acetylacetonate |
EE04224B1 (et) * | 1996-02-19 | 2004-02-16 | Nycomed Imaging As | Gaasi mikromullide dispersioon ja selle lüofiliseeritud jääk, ultraheli kontrastaine ja selle valmistamismeetod, mikromulle eraldav maatriks ning ultraheli kontrastaine kompositsioon |
US5611344A (en) * | 1996-03-05 | 1997-03-18 | Acusphere, Inc. | Microencapsulated fluorinated gases for use as imaging agents |
-
2000
- 2000-12-23 KR KR10-2000-0081255A patent/KR100373712B1/ko active IP Right Grant
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2015133828A1 (ko) * | 2014-03-07 | 2015-09-11 | 주식회사 퍼시픽시스템 | 약물 전달을 위해 기포를 포함하는 미셀 및 이를 제작하는 방법 |
KR20150105228A (ko) * | 2014-03-07 | 2015-09-16 | 주식회사 퍼시픽시스템 | 약물 전달을 위해 기포를 포함하는 미셀 및 이를 제작하는 방법 |
CN106102720A (zh) * | 2014-03-07 | 2016-11-09 | 太平洋系统有限公司 | 用于给药的含有气泡的胶团及其制备方法 |
KR20190108536A (ko) | 2014-03-07 | 2019-09-24 | 주식회사 퍼시픽시스템 | 약물 전달을 위해 기포를 포함하는 미셀 및 이를 제조하는 방법 |
Also Published As
Publication number | Publication date |
---|---|
KR100373712B1 (ko) | 2003-02-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Correas et al. | Ultrasound contrast agents: properties, principles of action, tolerance, and artifacts | |
Alkan-Onyuksel et al. | Development of inherently echogenic liposomes as an ultrasonic contrast agent | |
Calliada et al. | Ultrasound contrast agents: basic principles | |
JP2769077B2 (ja) | 診断イメージング剤およびその調製方法 | |
Raymond et al. | Broadband attenuation measurements of phospholipid-shelled ultrasound contrast agents | |
US6953569B2 (en) | Mixed gas microbubble compositions | |
AU627456B2 (en) | Ultrasonic contrast medium made up of small gas bubbles and fatty-acid-containing microparticles | |
US6106807A (en) | Use of methylenemalondiester derivatives for the production of gas-containing microparticles for ultrasound diagnosis, as well as media that contain said particles | |
US5976501A (en) | Use of pressure resistant protein microspheres encapsulating gases as ultrasonic imaging agents for vascular perfusion | |
JPH08502979A (ja) | 表面活性剤で安定化された微小気泡混合物、その製造方法およびその使用方法 | |
JPH0417164B2 (ko) | ||
JPH1171265A (ja) | 生体内に注入可能な安定な微小泡懸濁液 | |
EP0296189A1 (de) | Ultraschall-manometrieverfahren in einer flüssigkeit mittels mikrobläschen. | |
IE57272B1 (en) | Ultrasound contrast agent containing microparticles and gas micro-bubbles | |
JPH05255127A (ja) | 耐圧性気体封入微小気泡の長寿命懸濁物及びその製法 | |
JPS5879930A (ja) | 超音波診断用造影剤として使用する、生理学的に許容しうるガスで満たされた気泡の発生及び安定化用液体組成物及びその製造方法 | |
Nanda et al. | Echo-enhancing agents: safety | |
Forsberg et al. | Quantitative acoustic characterization of a new surfactant-based ultrasound contrast agent | |
Schlief et al. | Saccharide based contrast agents | |
Cosgrove | Echo enhancers and ultrasound imaging | |
KR100373712B1 (ko) | 초음파 조영제 및 그의 제조방법 | |
CN110639032B (zh) | 一种高频超声造影剂及其制备方法 | |
Schlief | Echo-enhancing agents: their physics and pharmacology | |
Reisner et al. | Contrast agents for myocardial perfusion studies: mechanisms, state of the art, and future prospects | |
Villarraga et al. | Contrast echocardiography 1996. A review. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20130212 Year of fee payment: 11 |
|
FPAY | Annual fee payment |
Payment date: 20140203 Year of fee payment: 12 |
|
FPAY | Annual fee payment |
Payment date: 20150813 Year of fee payment: 13 |
|
FPAY | Annual fee payment |
Payment date: 20151230 Year of fee payment: 14 |
|
FPAY | Annual fee payment |
Payment date: 20170112 Year of fee payment: 15 |
|
FPAY | Annual fee payment |
Payment date: 20171219 Year of fee payment: 16 |
|
FPAY | Annual fee payment |
Payment date: 20181226 Year of fee payment: 17 |